---
layout: post
title: "Final Decision on Withdrawal of MAKENA (Hydroxyprogesterone Caproate) and Eight Abbreviated New Drug Applications Following Public Hearing; Availability of Final Decision"
date: 2026-02-05 18:55:33 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-10264
original_published: 2023-05-15 00:00:00 +0000
significance: 8.00
---

# Final Decision on Withdrawal of MAKENA (Hydroxyprogesterone Caproate) and Eight Abbreviated New Drug Applications Following Public Hearing; Availability of Final Decision

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** May 15, 2023 00:00 UTC
**Document Number:** 2023-10264

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of the final decision withdrawing approval of MAKENA (hydroxyprogesterone caproate injection, 250 milligrams (mg) per milliliter (mL), once weekly), under the new drug application (NDA) 021945, held by Covis Pharma Group/Covis Pharma GmbH (Covis), and the eight abbreviated new drug applications (ANDAs) from multiple ANDA holders that reference NDA 021945. The Commissioner of Food and Drugs (the Commissioner) and the Chief Scientist jointly issued the decision following an October 2022 public hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/05/15/2023-10264/final-decision-on-withdrawal-of-makena-hydroxyprogesterone-caproate-and-eight-abbreviated-new-drug)
- API: https://www.federalregister.gov/api/v1/documents/2023-10264

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
